Marburg Virus Disease Epidemiology Forecast 2025-2034

Marburg virus disease (MVD), formerly called Marburg hemorrhagic fever, is a serious and often deadly illness in humans. The World Health Organization (WHO) reports that about 50% of people who get Marburg virus disease die from it. On March 21, 2023, government officials in Tanzania announced the country's first Marburg outbreak.

Marburg Virus Disease Epidemiology Forecast Report Coverage

The “Marburg Virus Disease Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Marburg virus disease. It projects the future incidence and prevalence rates of Marburg virus disease across various populations. The study covers age and type as major determinants of the Marburg virus disease-affected population. The report highlights patterns in the prevalence of Marburg virus disease over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Marburg virus disease in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Marburg Virus Disease Overview

Marburg virus disease is a severe illness caused by the Marburg virus, a type of filovirus closely related to the Ebola virus. It is a viral hemorrhagic fever and can cause bleeding, organ failure, and shock in affected individuals. The virus can be transmitted to humans through direct contact with infected bats or their droppings, handling or consuming bushmeat, and human-to-human transmission, usually through contact with bodily fluids of an infected person. The symptoms of Marburg virus disease are reported to appear suddenly, typically within 5 to 10 days after exposure to the virus.

Marburg Virus Disease: Treatment Overview

Currently, there is no specific treatment or vaccine for Marburg virus disease. Supportive care helps in improving the chances of survival for the infected individual. Fluids are given intravenously or orally to the patient to prevent dehydration, which is common due to vomiting and diarrhea. Medications are prescribed to reduce fever and manage pain. In cases of shock or low blood pressure, medications may be used to maintain blood pressure and ensure the organs receive enough blood. Several experimental treatments have also shown promise in laboratory and animal studies.

Epidemiology

The Marburg virus disease epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Marburg virus disease by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Marburg virus disease and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• As per the World Health Organization (WHO), the average fatality rate for Marburg virus disease is about 50%. In past outbreaks, the death rate has ranged from 24% to 88%. Early supportive care, including rehydration and treating symptoms, can help improve the chances of survival.
• On 27 September 2024, Rwanda's Ministry of Health reported the country's first outbreak of Marburg virus disease. By 2 October 2024, there were 36 confirmed cases, including 11 deaths.
• Marburg viruses are emerging and re-emerging across Africa, likely due to the geographical spread of the reservoir bats that carry the virus. Additionally, environmental factors and human behaviors are contributing factors.
• Major Marburg outbreaks were also reported in 2023. The first one occurred in February in Equatorial Guinea, with 16 confirmed cases and 12 deaths. Another outbreak happened in Tanzania in March, with 8 confirmed cases and 5 deaths.

Country-wise Marburg Virus Disease Epidemiology

The Marburg virus disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Marburg virus disease is influenced by a combination of ecological factors, human behavior, healthcare infrastructure, and the global movement of people and wildlife. One key factor in the spread of the Marburg virus is the presence of animal hosts, specifically the Rousettus aegyptiacus bat, which serves as the primary reservoir for the virus. The recent spread of the virus to countries like Tanzania, which is geographically distant from previous outbreak zones, shows how international travel, trade, and wildlife movement can contribute to the virus’s reach.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Marburg virus disease based on several factors.
• The Marburg Virus Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of Marburg virus disease are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of Marburg virus disease epidemiology in the 8 major markets?
• What will be the total number of patients with Marburg virus disease across the 8 major markets during the forecast period?
• What was the country-wise prevalence of Marburg virus disease in the 8 major markets in the historical period?
• Which country will have the highest number of Marburg virus disease patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Marburg virus disease during the forecast period of 2025-2034?
• What are the currently available treatments for Marburg virus disease?
• What are the disease risks, signs, symptoms, and unmet needs of Marburg virus disease?

This product will be delivered within 3-5 business days.